THE ENHANCED LIVER CIRRHOSIS TEST (ELF) ACCURATELY IDENTIFIES CIRRHOSIS IN PATIENTS WITH CHRONIC LIVER DISEASE

Abstract

Chronic liver disease (CLD) is the leading cause of death worldwide. That caused by Viral Hepatitis B and C (HBV, HCV), Alcoholic Liver Disease (ALD) and Non-Alcoholic Fatty Liver Disease (NAFLD). The present article provides an overview of the literature reporting some relevant biomarkers (ELF test) that have been found to be associated with liver fibrosis and that potentially may be used to predict the onset and/or monitor the progression of liver cirrhosis alternative the liver biopsy. This article provides an overview of the current published evidence on the clinical utility of the ELF test. This review collects the main evidence on the emerging role of Enhanced Liver Fibrosis (ELF) score as a prognostic marker of hepatitis, cirrhosis, and other liver diseases as the marker in cases of intoxication with organ phosphorus compounds and myocardial infarction or acute infections, and evidence that proves to use the Enhanced Liver Fibrosis as clinical practice presents an attractive alternative to both biopsy and imaging modalities that require significant high costs, also trained clinician.The most recent study proves that enhanced liver fibrosis score can be used instead of liver biopsy test and Transient Elastography for diagnosing liver fibrosis.

Keywords: Enhanced Liver Fibrosis Score, Transient Elastography, Liver, Liver Biopsy, Liver Diseases Alcoholic Liver Disease (ALD) and Non-Alcoholic Fatty Liver Disease (NAFLD).